Androgenetic alopecia (AGA) is the most common form of hair loss in both men and women. In the United States alone, approximately 80 million men and women suffer with this condition.
Human adipose tissue (fat) is a unique reservoir of multiple cell types including stem cells and other regenerative cells. A patient’s excess fat is easily collected and provides an abundant source of stem cells and other regenerative cells. The Kerastem technology prepares the patient’s therapy in real time and eliminates the costly process of shipping cells to an off-site facilities to grow and expand an adequate dose of cells.
Kerastem has initiated market development activities in Europe and Japan. Our US therapeutic pipeline is based upon a foundation of clinical studies and CE marked approved therapy options for patients with Alopecia outside the United States.1
1 Source: 2015 ISHRS: Hair Follicle Stimulation by Stromal Vascular Fraction Enhanced Adipose Transplantation in Baldness, David Perez-Meza, MD, FISHRS
Kerastem’s commercial plan complements Puregraft’s commercial and clinical success. As many of our existing Puregraft customers are thought leaders in the aesthetic marketplace, we believe a Puregraft user is also a potential customer for the Kerastem therapy.
How does Kerastem hair therapy work ?
The 3 steps process